| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/03/2004 | EP1392317A2 Substituted 1-benzazepines and derivatives thereof |
| 03/03/2004 | EP1392315A1 Methods of treating alzheimer's disease |
| 03/03/2004 | EP1392313A1 Combination comprising n- 5- 4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl -4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
| 03/03/2004 | EP1392312A1 TRIAZOLO 4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS |
| 03/03/2004 | EP1392311A1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 03/03/2004 | EP1392310A1 Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors |
| 03/03/2004 | EP1392308A1 Alpha-2-adrenergic agonist/fatty acid compositions |
| 03/03/2004 | EP1392307A1 Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene |
| 03/03/2004 | EP1392306A1 Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases |
| 03/03/2004 | EP1392305A2 Methods for treating neurodegenerative diseases including alzheimer's |
| 03/03/2004 | EP1392301A2 Prevention of addiction in pain management |
| 03/03/2004 | EP1392300A1 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors |
| 03/03/2004 | EP1392298A2 Fused heterocyclic compounds |
| 03/03/2004 | EP1392296A1 Thiazolidinediones alone or in conbination with other therapeutic agents for inhibiting or reducing tumour growth |
| 03/03/2004 | EP1392295A1 Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes |
| 03/03/2004 | EP1392293A1 Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
| 03/03/2004 | EP1392292A2 Pyranoindazoles and their use for the treatment of glaucoma |
| 03/03/2004 | EP1392291A2 Tripeptidyl peptidase inhibitors |
| 03/03/2004 | EP1392289A2 Caspase inhibitors and uses thereof |
| 03/03/2004 | EP1392288A2 Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus |
| 03/03/2004 | EP1392286A2 Antineoplastic combinations |
| 03/03/2004 | EP1392285A1 Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy |
| 03/03/2004 | EP1392280A2 Arylsulfonamide ethers, and methods of use thereof |
| 03/03/2004 | EP1392279A1 Trimethyl lock based tetrapartate prodrugs |
| 03/03/2004 | EP1392276A1 Potentiation of therapeutic effects of polyunsaturated fatty acids |
| 03/03/2004 | EP1392275A1 Use of protein and essential amino acids to treat amenorrhea and related disorders |
| 03/03/2004 | EP1392273A1 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg |
| 03/03/2004 | EP1392269A1 Novel arylaminopropane analogues and their use for the treatment of glaucoma |
| 03/03/2004 | EP1392265A2 Inhibitors of abc drug transporters at the blood-brain barrier |
| 03/03/2004 | EP1392264A1 Delivery of antiemetics through an inhalation route |
| 03/03/2004 | EP1392262A1 Delivery of drug esters through an inhalation route |
| 03/03/2004 | EP1392261A2 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 03/03/2004 | EP1392259A2 Delivery of erectile dysfunction drugs through an inhalation route |
| 03/03/2004 | EP1392257A1 Delivery of antihistamines through an inhalation route |
| 03/03/2004 | EP1392255A1 Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof |
| 03/03/2004 | EP1392254A1 Micellar drug delivery systems for hydrophobic drugs |
| 03/03/2004 | EP1392252A2 Pharmaceutical composition containing stool softener such as polaxamer and enteric coated particles of bisacodyl |
| 03/03/2004 | EP1392230A1 Methods for treating or preventing diseases of the oral cavity |
| 03/03/2004 | EP1284974B1 Triazolyl tropane derivatives as ccr5 modulators |
| 03/03/2004 | EP1282624B1 Crf receptor antagonists and methods relating thereto |
| 03/03/2004 | EP1202717B1 Use of naaladase inhibitors for treating anxiety and memory disorders |
| 03/03/2004 | EP1196440B1 Therapeutic peptides derived from subsequences of bpi |
| 03/03/2004 | EP1187617B1 Method for selecting the concentration of an amphipathic antihistamine drug by determining the drug's surface activity rating |
| 03/03/2004 | EP1162953B1 Mechanically stable pharmaceutical presentation form containing liquid or semi-solid surface-active substances |
| 03/03/2004 | EP1119252A4 Use of melanin for inhibition of angiogenesis and macular degeneration |
| 03/03/2004 | EP1109571B1 Methods of treating salt-dependent hypertension |
| 03/03/2004 | EP1062224A4 Modified factor viii |
| 03/03/2004 | EP1047437A4 Sea cucumber carotenoid lipid fraction products and methods of use |
| 03/03/2004 | EP1045839B1 Novel amines as pharmaceutical agents |
| 03/03/2004 | EP1042354B1 Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use |
| 03/03/2004 | EP1037655B1 use of novel ligands of the neuropeptide receptor hfgan72 and antagonists thereof in therapy |
| 03/03/2004 | EP1011716B9 Neuromedin b receptor antagonists |
| 03/03/2004 | EP0998460B1 Novel tetrazole derivatives |
| 03/03/2004 | EP0986386B1 Use of nitrogen heterocyclic aromatic derivatives in the topical treatment of the epithelial tissues diseases |
| 03/03/2004 | EP0865430B1 3-(4-subst.-piperidinyl-1)-1-(3,4-dichlorophenyl)propyl carbamates and ureas and derivatives as novel neurokinin antagonists |
| 03/03/2004 | EP0853617B1 Novel 2,3-dioxo-1,2,3,4-tetrahydro-quinoyxalinyl derivatives |
| 03/03/2004 | EP0839033B1 Use of l-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral |
| 03/03/2004 | EP0733103B1 Generation of high titers of recombinant aav vectors |
| 03/03/2004 | EP0636028B1 Self-assembling polynucleotide delivery system comprising an amphiphatic cationic peptide |
| 03/03/2004 | EP0613375B1 Pharmaceutical lysine-containing polypeptide compositions and the use thereof |
| 03/03/2004 | CN1479872A Materials and methods to modulate ligand binding/enzymatic activity of alpha/beta proteins containing allosteric regulatory site |
| 03/03/2004 | CN1479739A Heterocyclic ether substituted imidazoquinolie compounds |
| 03/03/2004 | CN1479738A Thioether subsituted imidazoquinoline compound |
| 03/03/2004 | CN1479737A Ethanolates of sodium-proton exchanger protein type-1 inhibitor |
| 03/03/2004 | CN1479736A Benzofuran and benzothiophene derivatives |
| 03/03/2004 | CN1479728A Pexoxisome proliferator activated receptor alpha agonists |
| 03/03/2004 | CN1479722A Guanidine and amidine derivatives as factor Xa inhibitors |
| 03/03/2004 | CN1479712A Ketone compounds and compositions for cholesterol management and related uses |
| 03/03/2004 | CN1479654A Method for coating high-efficient ingredient on partial or complete in implants and on plants |
| 03/03/2004 | CN1479630A Method of inducing cancer cell death and tumor regression |
| 03/03/2004 | CN1479629A Combinations and compositions which interfere with VEGF/VEFG and anglopoietin/Tie receptor function and their use (II) |
| 03/03/2004 | CN1479628A Use of CYP206 inhibitors in combination therapies |
| 03/03/2004 | CN1479624A Process for preparing aqueous extracts of plants and extracts so obtained |
| 03/03/2004 | CN1479623A Antimonocytic activity of extracts of piper betel leaves |
| 03/03/2004 | CN1479619A Use of pyrazolo [4,3-d] pyrimidines |
| 03/03/2004 | CN1479618A Treatment of sexual dysfunction using boonbesin antagonist |
| 03/03/2004 | CN1479611A Pharmaceutical paste comprising acid-labile activeingredient |
| 03/03/2004 | CN1479578A Anticholesterolemic edible oil |
| 03/03/2004 | CN1478783A Inositol polyphosphate ester derivative and its using method |
| 03/03/2004 | CN1478543A Therapeutic use of bactericidal/permeability improving protein product |
| 03/03/2004 | CN1478541A Design of high effect blood vessel production inhibitor and its application |
| 03/03/2004 | CN1478503A Antisenility preparation |
| 03/03/2004 | CN1140536C Minotopes and anti-mimotopes of human platelet glycoprotein Ib/Ix |
| 03/03/2004 | CN1140527C Phenyl xanthine ester and amide derivatives |
| 03/03/2004 | CN1140526C 8-azabicyclo[3,2,1] octane-3-methanamine derivatives as ligands of D2 and D3 doppamine and 5HT1A and 5HT2 serotonin receptors |
| 03/03/2004 | CN1140525C 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| 03/03/2004 | CN1140516C Quinoline and quinoxaline compounds which inhibits platelet-derived growth factor on/or p56lck tyrosine kinases |
| 03/03/2004 | CN1140508C Substed 4-biphenyl-4-hydroxybutyric acid derivs, and matrix metalloprotease inhibitors |
| 03/03/2004 | CN1140503C Triazepiones, compound process for their preparation and their therapeutic application |
| 03/03/2004 | CN1140283C Medicine for preventing and treating lupus erythematosus and other immunological disease |
| 03/03/2004 | CN1140269C Bicyclic compounds capable of inhibiting tyrosine kinases of epidermal growth factor receptor family |
| 03/03/2004 | CN1140182C Coca components, edible products having enhanced polyphenol content, methods of making same and medical us |
| 03/02/2004 | US6699997 Carvedilol |
| 03/02/2004 | US6699910 Ketone compounds and compositions for cholesterol management and related uses |
| 03/02/2004 | US6699904 PPAR agonists |
| 03/02/2004 | US6699903 Hydration of the anhydrous lithium salt with acetonitrile and water; phosphodiesterase inhibitors |
| 03/02/2004 | US6699899 Substituted acylhydroxamic acids and method of reducing TNFα levels |
| 03/02/2004 | US6699893 Glucocorticoid receptor modulators |
| 03/02/2004 | US6699891 Npyy5 antagonists |
| 03/02/2004 | US6699885 Substituted benzimidazole dosage forms and methods of using same |